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A variety of pathological conditions can increase risk for development of ventricular arrhythmias 
in humans including diabetes, obesity, myocardial infarction (MI), and heart failure. Many of 
these diseases involve global disruption of the autonomic nervous system, including increased 
sympathetic drive and parasympathetic withdrawal, but another common factor among these 
disorders is sympathetic dysfunction within the heart.  Treatments that target cardiac 
sympathetic transmission, including beta blockers and ganglionectomy, prolong life and 
decrease arrhythmias 1-5.   
 
Sympathetic control of the heart under normal conditions occurs primarily via norepinephrine 
(NE) acting on β adrenergic receptors (β-AR) to stimulate increases in heart rate (chronotropy), 
conduction velocity (dromotropy), and contractility (inotropy). These positive effects of 
sympathetic stimulation allow myocytes to meet increased cardiac demands during stress or 
exercise, serving to maintain homeostasis. The nervous system adapts to changing conditions, 
however, and sympathetic neurons undergo structural and functional alterations in response to 
injury and disease. There are at least four types of sympathetic remodeling that occur during 
conditions of increased arrhythmia susceptibility: hyperinnervation (increased nerve density), 
denervation (decreased nerve density), altered neurotransmitter or neuropeptide production, 
and increased neuronal excitability. Rubart and Zipes proposed a model to explain how these 
diverse changes in sympathetic transmission might contribute to arrhythmia generation 6, 
suggesting that inappropriate heterogeneity of NE release within the heart leads to differential 
electrical remodeling of cardiac myocytes and predisposes the heart to electrical instability. 
Many studies now support the hypothesis that heterogeneity of noradrenergic transmission 
increases the risk of arrhythmia, and have identified some of the mechanisms that underlie 
neuronal remodeling. This review will examine the mechanisms of sympathetic remodeling and 
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will connect neural changes to increased arrhythmia susceptibility. We will focus on ventricular 
arrhythmias, as atrial arrhythmias were reviewed recently 7. 
 
Hyperinnervation and excess NE release 
Regional hyperinnervation was the first type of neural remodeling linked to arrhythmia 
generation in humans 8, 9.  Areas of sympathetic hyperinnervation, defined as increased nerve 
fiber density compared to control tissue, have now been identified in many conditions with 
increased arrhythmia susceptibility including heart failure 9, myocardial infarction 10, 11, spinal 
cord injury 12, and diet induced obesity13, 14. Nerve growth factor (NGF) has been the focus of 
studies related to cardiac hyperinnervation since NGF stimulates the extension, or sprouting, of 
sympathetic nerve endings during development and after injury. Cardiac NGF is elevated in 
animal and human hearts during conditions associated with hyperinnervation 10, 12, 15, and is 
decreased in conditions that include a loss of functional sympathetic innervation such as late 
stage heart failure 16 and diabetic neuropathy 17.  
 
Sympathetic axon outgrowth is triggered through activation of the TrkA (Tropomyosin receptor 
kinase A) receptor, which stimulates serine phosphorylation of STAT3 (signal transducer and 
activator of transcription 3) in addition to activating other signaling pathways. Although TrkA can 
be activated by both NGF and Neurotrophin 3 during development, NGF is the only ligand that 
activates TrkA in mature sympathetic neurons, and thus is crucial for maintaining sympathetic 
neuron health and stimulating axon regeneration. Recent studies indicate that cytokines like 
Leukemia Inhibitory Factor (LIF) and Cardiotrophin-1 (CT-1), which activate the gp130 receptor, 
do not stimulate axon growth on their own but are required for maximal NGF-induced 
sympathetic axon extension 18. These cytokines stimulate tyrosine phosphorylation of STAT3, 
and phosphorylation of STAT3 on both serine and tyrosine is required for maximal axon 
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outgrowth 18. The related cytokine leptin also enhances sympathetic axon outgrowth 19, and may 
contribute to the cardiac hyperinnervation observed in diet-induced obesity.  
 
Pathological conditions resulting in hyperinnervation within the heart are also associated with 
increased sympathetic drive from the CNS, and enhanced excitability of post-ganglionic neurons 
may also contribute to elevated adrenergic transmission in the heart. Neuronal cell size is 
increased significantly in stellate ganglia removed from humans with ischemic and non-ischemic 
cardiomyopathy compared to control ganglia 20, and similar changes identified in canines 
coincide with increased neuronal excitability 21. Similarly, increased dendrite field size and 
synapse number contribute to elevated cardiac sympathetic tone in rats following T5 spinal cord 
transection 22. Retrograde signaling by NGF regulates synapse formation during development 23 
and high NGF likely contributes to increased cell size and synapse formation after injury. NGF 
may also increase sympathetic excitability by altering sensitivity to inflammatory mediators 24, 
and by altering neuronal firing properties 25. Interestingly, statins decrease sympathetic neuron 
excitability by stimulating dendrite retraction 26, raising the possibility that dampening 
sympathetic drive via peripheral actions contributes to their therapeutic value in patients with 
cardiovascular disease. 
 
Functional noradrenergic transmission requires a balance between NE synthesis, release, and 
reuptake, each of which can be regulated independently 27. For example, after myocardial 
infarction newly sprouting sympathetic fibers have low NE content 28, but there is a paradoxical 
increase in extracellular NE 27. This can be explained in part by elevated NE synthesis and 
release in other regions of the heart that are not matched by a similar increase in NE removal 11. 
Such functional changes have been identified in patients with heart failure, where increased NE 
release as well as decreased NE reuptake contribute to a buildup of extracellular NE and 




Myocardial responses to acute hyperinnervation/excess NE 
Norepinephrine released from sympathetic nerves activates cardiac β-AR to modulate myocyte 
repolarization and contractility. Sympathetic nerves are not distributed evenly across the heart, 
but are most dense near the base of the ventricles. Likewise, the epicardial to endocardial 
gradient in cardiac action potential duration (APD) 30-32 that is critical for normal activation and 
repolarization of the left ventricle is regulated by innervation, and disrupting the normal 
organization of sympathetic nerves in an otherwise healthy heart is arrhythmogenic 33, 34.  
Activation of cardiac β-AR modulates myocyte repolarization by altering transmembrane 
currents and Ca2+ homeostasis 35-37. -AR stimulated cAMP leads to phosphorylation of proteins 
involved in excitation-contraction coupling including phospholamban, L-type Ca2+ channels, and 
ryanodine receptors (RyR), resulting in increased sarcoplasmic reticulum (SR) Ca2+-ATPase 
(SERCA) activity and an increase in SR Ca2+ content38. Thus, during sympathetic stimulation 
more Ca2+ is released from the SR39 to activate the myofilaments, increasing contractility, but 
spontaneous Ca2+ release from the SR also becomes more likely 40, 41. Therefore, the positive 
inotropic effects of sympathetic stimulation that allow myocytes to meet increased cardiac 
demands are accompanied by an increased risk for pathological arrhythmias via focal 
(triggered) mechanisms. 
 
At the cellular level, focal activity during sympathetic activation is likely due to delayed 
afterdepolarizations (DADs),42 which are membrane depolarizations occurring during phase 4 of 
the action potential. The increased cytosolic and SR Ca2+ levels that occur during sympathetic 
activation can lead to SR Ca2+ overload (Figure 1), which may result in spontaneous opening of 
RyRs and Ca2+ release that is not in response to an action potential. This leads to Ca2+ 
extrusion from the cytosol via the Na+/Ca2+ exchanger (NCX).43  NCX is electrogenic, extruding 
one Ca2+ ion (2+) in exchange for 3 Na+ ions (3+), which produces a net inward current. If the 
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inward current is large enough, the cell membrane depolarizes and a triggered action potential 
may occur. 
 
At the tissue level, several thousand cells must all experience DADs simultaneously in order to 
generate enough depolarizing current to produce a propagating action potential (called the 
‘source-sink mismatch’).44, 45 Recent studies revealed that local application of β-AR agonists 
such as NE or isoproterenol can induce premature ventricular complexes (PVCs) and sustained 
focal VT in intact hearts,46-49 providing a mechanistic link between the numerous experimental 
and clinical investigations that have found regional hyperinnervation accompanied by increased 
arrhythmia risk. 8  Furthermore, electrophysiological remodeling of cardiac myocytes in 
response to myocardial infarction or heart failure can cause changes (e.g., increased 
expression of NCX,50 increased SR Ca2+ leak through RyR,51 decreased inward rectifying K+ 
current,43 decreased gap junction coupling,52 and fibrosis) that further increase the likelihood of 
DADs and arrhythmia generation in response to localized sympathetic stimulation. 45, 46  
 
Sympathetic stimulation also has effects on ionic currents that impact the ventricular action 
potential and risk for reentrant arrhythmias. The effects of adrenergic activation on individual ion 
channels have been reviewed elsewhere53, 54, but one of the best-known features of β-AR 
stimulation is an increase in L-type Ca2+ current via phosphorylation of the channel (Cav1.2).55  
This effect, by itself, is expected to increase APD, but is counterbalanced by the effect of β-AR 
on K+ currents, most notably an increase in IKs, although IKr may also be involved.56, 57  The net 
effect of NE typically results in a shortening of the APD, a requirement for the heart to beat at 
faster rates during sympathetic activity.  Due to the base to apex gradient in cardiac sympathetic 
nerves, however, sympathetic activation results in non-uniform changes in APD throughout the 
ventricle. For example, sympathetic nerve stimulation in a normal rabbit heart led to increased 
dispersion of repolarization and reversed the direction of the repolarization wavefront.58 
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Administration of the β-AR agonist isoproterenol generated a different set of responses, 
suggesting that the dramatic changes in repolarization observed with sympathetic nerve 
stimulation were not due to differences in β-AR distribution or sensitivity, but rather due to the 
heterogeneous distribution of the nerves. 58 Similar results have been obtained in porcine 
ventricles, where dramatically different spatial patterns of activation-recovery intervals (ARIs, 
surrogate measure for APD) and repolarization were observed in response to sympathetic nerve 
stimulation vs. circulating NE59, 60. Thus, even under non-pathological conditions, considerable 
heterogeneity of sympathetic nerve distribution leads to increased dispersion of repolarization 
and potential for reentrant arrhythmias. Therefore, in conditions of maladaptive nerve 
remodeling, significantly greater heterogeneity of APD and repolarization may exist.  Indeed, 
sympathetic stimulation after myocardial infarction not only caused increased dispersion of 
repolarization compared to controls, but activation and propagation patterns were also altered 
significantly 61. This was confirmed in patients with MI in whom reflex sympathetic stimulation 
caused a 230% increase in dispersion of repolarization compared to patients with structurally 
normal hearts.62 
 
Myocardial responses to chronic hyperinnervation/excess NE 
Acute effects of sympathetic activation often occur on a background of remodeled myocardial 
properties induced by heart failure or MI, but alterations to sympathetic transmission can also 
lead to chronic remodeling of the myocardium.  Sympathetic hyperinnervation and elevated 
sympathetic tone are key features of many cardiovascular diseases.  In these conditions the 
myocardium becomes less responsive to adrenergic stimulation over time, and simultaneously 
less capable of maintaining adequate cardiac output, which further increases sympathetic drive 
from the CNS.  The loss of cardiomyocyte responsiveness to adrenergic stimulation is a 
hallmark of sustained adrenergic stimulation and hyperinnervation 63. Several factors contribute 
to this loss of sensitivity, including down-regulation of the receptor itself 64, but an especially 
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important regulator of β-AR activity is the G-protein receptor kinase 2 (GRK2, also known as 
βARK1). Acutely, GRK2 is activated by PKA in response to adrenergic stimulation and acts to 
inhibit β-AR activity in a self-contained negative feedback loop. Sustained activation of β-AR in 
adult mice, however, leads to increased GRK2 expression 64. A similar increase in GRK2 is 
seen in canine heart failure, where it is reversed by sympathetic denervation, confirming 
regulation of GRK2 by sympathetic transmission 65. Long term activation of β-AR also leads to 
G-protein uncoupling and a reduction of Gαs protein 66, as well as a reduction of repolarizing K+ 
current 67, 68.  Thus, sustained activation of adrenergic receptors leads to adaptations that limit 
myocyte sensitivity to adrenergic stimulation and alter ion channel expression. Long term 
treatment with beta blockers blunts many of these adaptations 63 and normalizes myocyte 
calcium handling 69, contributing to the well-established protective effects of sympathetic 
blockade 1-4.  
 
Cardiac denervation and axon degeneration  
The mechanisms by which too much sympathetic transmission can be toxic for the heart are 
well-characterized, but the local loss of sympathetic transmission within the heart also 
contributes to rhythm instability. Regional deficits in sympathetic transmission, identified in 
patients by imaging the uptake of labeled NE transporter substrates, have been observed in 
several pathological conditions including myocardial infarction 70, 71, heart failure 72, and 
Parkinson’s Disease 73. Several recent clinical studies suggest that sympathetic denervation 
after MI predicts the probability of serious ventricular arrhythmias 74-76, and a detailed electrical 
mapping study in human hearts revealed that sympathetic denervation of the normal 
myocardium adjacent to the scar resulted in β-AR agonist super-sensitivity and increased 




Paradoxically, members of the neurotrophin family of growth factors can be involved in the 
destruction of sympathetic nerves following cardiac injury. While the neurotrophin NGF 
stimulates TrkA in sympathetic neurons to promote axon maintenance and process outgrowth, 
its precursor protein ProNGF, which is elevated in the human heart after MI 77, activates the p75 
neurotrophin receptor (p75NTR; also called TNF receptor super family 16, TNFRS16), to trigger 
axon degeneration 78, 79 (Figure 2). Similarly, ProBDNF (Pro Brain Derived Neurotrophic Factor) 
and BDNF selectively activate p75NTR on sympathetic neurons to stimulate axon degeneration 
80. The Trk tyrosine kinase receptors and p75NTR have opposing actions not just in cardiac 
sympathetic nerves81, but also in the coronary vasculature 77 and cardiac myocytes 15, 82. Thus, 
ProNGF activation of p75NTR after MI leads to the loss of nerve fibers in viable myocardium 81 
as well as microvascular damage and scar extension 77.   
 
While activation of p75NTR can contribute to the loss of cardiac nerves, other factors are 
involved in sustaining denervation. Chondroitin sulfate proteoglycans (CSPGs) are produced in 
the cardiac scar after ischemia-reperfusion, where they prevent reinnervation of the border zone 
and scar 83. This contrasts with the scar that forms after sustained ischemia, which is devoid of 
CSPGs 83 and receives sympathetic hyperinnervation 10, 27. Removing or inhibiting the CSPG 
receptor protein tyrosine phosphatase receptor sigma (PTPσ) in mice leads to reinnervation of 
the scar and border zone, restoring normal NE content and β-AR responsiveness to that region 
of the damaged left ventricle 84. Consistent with the human studies linking post-MI denervation 
to arrhythmia risk, restoring innervation throughout the scar and border zone in mouse heart 
normalizes post-MI calcium handling and decreases arrhythmia susceptibility 84.  
 
Myocardial responses to chronic denervation  
Just as sympathetic hyperinnervation can alter the molecular makeup of myocytes, sustained 
sympathetic denervation has similarly profound effects. One of the best characterized changes 
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is a loss of the transient outward K+ current Ito, which is responsible for the initial repolarization 
in phase 1 of the action potential. Sympathetic denervation in rat decreases Ito by lowering 
expression of several different K+ channel subunits, and increases susceptibility to ventricular 
fibrillation 85, 86. Decreased Ito is also observed in disease states characterized by sympathetic 
denervation including Chagas disease, diabetic neuropathy, and myocardial infarction 84, 87, 88. 
Restoring adrenergic transmission in Chagas animals with NE infusion 89, or promoting 
sympathetic re-innervation of denervated infarct and border zone tissue 84 reverses the loss of 
Ito.  
  
The consequences of sympathetic denervation are not limited to the transient outward K+ 
current. While hyperinnervation increases GRK2, sustained treatment with the beta blocker 
atenolol in mice90 and surgical sympathectomy in dogs65 leads to GRK2 down-regulation. This 
reduction in GRK2 may play an important role in the β-AR supersensitivity observed following 
sympathetic denervation, as GRK2 knock out mice exhibit a similar supersensitivity91. The 
absence of GRK2 also alters Ca2+ homeostasis by reducing SERCA activity, which leads to 
reduced SR Ca2+ load and increased cytosolic Ca2+ levels, thus increasing NCX activity91. 
Increased activity of the electrogenic NCX can initiate DADs, and the adrenergic supersensitivity 
that accompanies decreased GRK2 increases the likelihood that β-AR stimulation will be 
sufficient to overcome source-sink mismatch and generate focal arrhythmia47. Consistent with 
this possibility, isoproterenol stimulation of hearts after MI triggers focal arrhythmias that arise 
from denervated tissue near the infarct, while release of NE from sympathetic nerves in the 
same hearts does not trigger arrhythmias 84. Restoration of sympathetic innervation to the scar 
and border zone of infarcted hearts prevents isoproterenol-induced arrhythmias and abnormal 
Ca2+ handling, confirming a role for denervation induced β-AR super-sensitivity in arrhythmia 
generation 84. Sudden cardiac death is most common in the morning 92 when circulating 
catecholamines are rising rapidly 93, suggesting that high circulating NE and epinephrine trigger 
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arrhythmias in denervated myocardium via activating super-sensitive β-AR signaling pathways. 
Thus, denervation and hyperinnervation may trigger arrhythmias via similar mechanisms within 
cardiac myocytes. 
 
Neurotransmitter and neuropeptide production  
In addition to the loss or gain of nerve fibers, sympathetic neurons innervating the heart can 
undergo changes in neurotransmitter and peptide production and release following injury. 
Sympathetic nerves in the heart produce the peptide co-transmitter neuropeptide Y (NPY), 
which inhibits release of ACh from cardiac parasympathetic nerves 94 and causes 
vasoconstriction on the cardiac vasculature 95. NPY is elevated after MI 96, and high plasma 
NPY levels in patients with acute ST elevation MI correlate with increased microvascular 
resistance following reperfusion 97. NPY is released during periods of high sympathetic drive, 
and in the context of myocardial infarction high levels of sympathetic activation resulting in NPY 
release appears to be detrimental for the heart. Over a longer time frame, cardiac damage can 
lead to changes in neuropeptide and neurotransmitter expression in sympathetic neurons. The 
best characterized change in sympathetic transmission is a developmental transition from 
production of NE to ACh due to the actions of gp130 cytokines 98. Recent studies revealed a 
similar change in phenotype triggered by cytokines like LIF and CT-1 during heart failure 99. 
Stellate ganglia obtained from humans with heart failure also exhibited expression of proteins 
associated with cholinergic transmission 99, suggesting that cholinergic sympathetic 
transmission can occur in the human heart. Although the functional consequences of ACh 
release from sympathetic nerves are unclear, NE and ACh have opposing effects on ventricular 
action potential duration (NE shortens whereas ACh lengthens). Thus, cholinergic sympathetic 
transmission may indeed be arrhythmogenic by limiting the adaptation of the action potential 
duration to increased heart rates during sympathetic activity.  Therefore, the functional impact of 





Interactions between sympathetic neurons and cardiac myocytes can become destructive in 
pathophysiological conditions, giving rise to electrical instability and increased arrhythmia 
susceptibility. We have summarized the most common changes that occur in cardiac 
sympathetic neurons during pathologies associated with increased ventricular arrhythmia risk, 
and how altered neurotransmission might contribute to arrhythmia generation. Many relevant 
studies were excluded due to reference limits, but we have tried to cite work from different 
laboratories who have contributed to our understanding. Interventions that target the 
sympathetic innervation of the heart have been successful in treating arrhythmias, and our hope 
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Figure Legends  
 
Figure 1. Hyperinnervation and denervation can both contribute to arrhythmias. Acute 
hyperinnervation or excess NE (Top) leads to increased activation of β-ARs (beta adrenergic 
receptors) and subsequent changes in Ik and calcium overload. β-AR signaling increases Ik 
which shortens action potential duration (APD). At the same time, intracellular Ca2+ rises due to 
enhanced influx via the L-type Ca2+ channel and increased release from the sarcoplasmic 
reticulum (SR). Extrusion of Ca2+ from the cytosol via the Na+/Ca2+ exchanger (NCX) produces a 
net inward current leading to delayed afterdepolarizations (DADs). In contrast, chronic 
hyperinnervation leads to desensitization of β-AR signaling and decreased Ik. Chronic 
denervation (Bottom) results in β-AR supersensitivity and decreased Ito. Activation of super-
sensitive β-AR signaling pathways by circulating epinephrine leads to calcium overload and 
DADs. 
 
Figure 2. Neurotrophins stimulate different effects in sympathetic neurons via activation 
of p75NTR and/or TrkA.  Pro-Neurotrophins like ProNGF and ProBDNF are processed to 
mature neurotrophins (NGF, BDNF) by intra- and extra-cellular proteases. Activation of a 
p75NTR/Sortilin receptor complex by ProNGF or ProBDNF, or activation of p75NTR by BDNF, 
stimulates axon degeneration in sympathetic neurons. In contrast, NGF signaling via TrkA or a 
TrkA/p75NTR receptor complex stimulates sympathetic axon maintenance and growth.  
 
 
